Analysis of related factors for RA flares after SARS-CoV-2 infection : a retrospective study from patient survey
© 2024. The Author(s)..
SARS-CoV-2 and its variants are widely prevalent worldwide. With frequent secondary and breakthrough infections, immune dysfunction in RA patients, and long-term use of immune preparations, SARS-CoV-2 infection poses a significant challenge to patients and rheumatologists. Whether SARS-CoV-2 infection causes RA flares and what factors aggravate RA flares are poorly studied. A questionnaire survey was conducted on RA patients infected with SARS-CoV-2 after December 7, 2022, in China through a multicenter and inter-network platform regarding general personal condition, primary disease, comorbidity, SARS-CoV-2 vaccination, viral infection, and impact on the primary disease. A total of 306 RA patients were included in this study, and the patient data were analyzed, in which the general condition of RA patients, medication use before SARS-CoV-2 infection and post-infection typing and manifestations, and medication adjustment did not affect the Flare of RA patients after SARS-CoV-2 infection. The control of disease before SARS-CoV-2 infection (OR = 2.10), RA involving pulmonary lesions (OR = 2.28), and the recovery time of COVID-19 (OR = 2.50) were risk factors for RA flare. RA involving pulmonary lesions, control status of disease before infection, and recovery time of COVID-19 disease are risk factors for RA flare after SARS-CoV-2 infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Scientific reports - 14(2024), 1 vom: 20. Feb., Seite 4243 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Rong [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 22.02.2024 Date Revised 24.02.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41598-024-52748-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368689085 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368689085 | ||
003 | DE-627 | ||
005 | 20240229150200.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240222s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41598-024-52748-3 |2 doi | |
028 | 5 | 2 | |a pubmed24n1304.xml |
035 | |a (DE-627)NLM368689085 | ||
035 | |a (NLM)38378889 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Rong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Analysis of related factors for RA flares after SARS-CoV-2 infection |b a retrospective study from patient survey |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.02.2024 | ||
500 | |a Date Revised 24.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a SARS-CoV-2 and its variants are widely prevalent worldwide. With frequent secondary and breakthrough infections, immune dysfunction in RA patients, and long-term use of immune preparations, SARS-CoV-2 infection poses a significant challenge to patients and rheumatologists. Whether SARS-CoV-2 infection causes RA flares and what factors aggravate RA flares are poorly studied. A questionnaire survey was conducted on RA patients infected with SARS-CoV-2 after December 7, 2022, in China through a multicenter and inter-network platform regarding general personal condition, primary disease, comorbidity, SARS-CoV-2 vaccination, viral infection, and impact on the primary disease. A total of 306 RA patients were included in this study, and the patient data were analyzed, in which the general condition of RA patients, medication use before SARS-CoV-2 infection and post-infection typing and manifestations, and medication adjustment did not affect the Flare of RA patients after SARS-CoV-2 infection. The control of disease before SARS-CoV-2 infection (OR = 2.10), RA involving pulmonary lesions (OR = 2.28), and the recovery time of COVID-19 (OR = 2.50) were risk factors for RA flare. RA involving pulmonary lesions, control status of disease before infection, and recovery time of COVID-19 disease are risk factors for RA flare after SARS-CoV-2 infection | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Journal Article | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
700 | 1 | |a Zhao, Jun-Kang |e verfasserin |4 aut | |
700 | 1 | |a Li, Qian |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Li |e verfasserin |4 aut | |
700 | 1 | |a Su, Ya-Zhen |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Jun-Yan |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Li-Yun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 14(2024), 1 vom: 20. Feb., Seite 4243 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:20 |g month:02 |g pages:4243 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-024-52748-3 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2024 |e 1 |b 20 |c 02 |h 4243 |